AbbVie Biotherapeutics, Redwood City, CA, USA.
Expert Rev Clin Pharmacol. 2014 Jan;7(1):9-19. doi: 10.1586/17512433.2014.865516. Epub 2013 Dec 2.
Daclizumab is a monoclonal antibody specific for the IL-2R α chain (CD25). Daclizumab has been observed to have multiple mechanisms of action, which may contribute to beneficial effects in immune-related disease and particularly in relapsing and remitting multiple sclerosis (RRMS). These include inhibition of activated immune cells, increase of regulatory natural killer cells, effects on dendritic cells, inhibition of innate lymphoid tissue inducer cells and altered responses involving IL-2 transpresentation. The antibody has shown considerable promise in open-label and early Phase II clinical trials when used as a monotherapy, or in combination with IFN-β. In recently completed randomized trials in RRMS, treatment with daclizumab monotherapy compared with placebo resulted in clinically meaningful and statistically significant reductions in relapses, active lesions on brain MRI and slowing of disability progression. A large Phase III trial in RRMS is ongoing.
达利珠单抗是一种针对白细胞介素 2 受体 α 链（CD25）的单克隆抗体。达利珠单抗具有多种作用机制，这可能有助于免疫相关疾病的有益效果，特别是在复发缓解型多发性硬化症（RRMS）中。这些机制包括抑制激活的免疫细胞、增加调节性自然杀伤细胞、对树突状细胞的影响、抑制固有淋巴样组织诱导细胞以及改变涉及白细胞介素 2 转染的反应。该抗体在开放标签和早期 II 期临床试验中作为单药或与 IFN-β 联合使用时表现出很大的前景。在最近完成的 RRMS 随机试验中，与安慰剂相比，达利珠单抗单药治疗导致复发、脑 MRI 上的活动性病变以及残疾进展速度减慢具有临床意义和统计学意义的降低。一项针对 RRMS 的大型 III 期试验正在进行中。
